Clinical Trials
Below are current clinical trials.
203 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The purpose of this study is to determine if Clofazimine is effective in treating patients with drug resistant non-tuberculous mycobacterial infections.
-
Rochester, Minn.
The purpose of this study is to determine the safety and tolerability of ixazomib in HIV infected patients who are on a stable regimen of ART that suppresses HIV replication, and to determine the effectiveness of ixazomib on reservoir T cells that are infected with HIV DNA.
-
Rochester, Minn., La Crosse, Wis., Albert Lea, Minn.
To conduct a prospective, multicenter, observational study of patients with well-characterized alcoholic hepatitis (AH) and frequency matched individuals (by age, gender, and race) with comparable history of alcohol consumption but no clinical evidence of liver disease (controls). At the end of the study, a robust clinical information, central bio-repository will be developed from both cases and controls.
-
Rochester, Minn.
We purpose of this study is to evaluate the diagnosis accuracy of the Controlled Attenuation Parameter (CAP) measured by FibroScan® (both with M and XL probes) in all patients who are undergoing liver biopsy for any liver disease.
-
Jacksonville, Fla.
The purpose of this study is to evaluate Lamprene (Clofazimine) to treat non-tuberculous mycobacterial (NTM) infections.
-
Jacksonville, Fla.
Stage A: To evaluate the safety and efficacy of the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in adult patients who require RBC transfusion support. Stage B: To provide early access to the INTERCEPT pathogen reduction system for RBC in regions where a substantial proportion of the population has been infected or is at risk of infection by the Zika virus (ZIKV), and the risk of asymptomatic infection among qualified blood donors is recognized. Besides the reduction of risk of transfusion transmitted ZIKV, the intent of the study is also to reduce the risk of transfusion-transmitted infections (TTI) in general, including transfusion related sepsis and other emerging or concurrent endemic pathogens (e.g. Dengue and Chikungunya), and to reduce the risk of TA-GVHD. As part of this treatment use study, additional data will be provided on the safety of INTERCEPT-treated RBCs (IBS RBCs) supplied for routine clinical transfusion practice.
-
Rochester, Minn.
The purpose of this study is to understand how transitioning to telework due to COVID-19 impacts employee satisfaction in one health care facility and how select non-clinical employees describe their experiences after transitioning from an in-person work environment to telework.
-
Rochester, Minn.
The purpose of this study is to look at the use of a novel biofeedback-assisted meditation device when used during the day to provide mindfulness training if it can increase calm state brain activity in post-Covid patients.
-
Rochester, Minn.
The aim of this study is to identify difficult to diagnose microbial pathogens causing infections using blood or urine for identification of bacteria, viruses, fungi or parasites that are not detectable or are difficult to detect using current diagnostic techniques.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to understand when patients are shedding active COVID virus RNA as detectable by viral culture, and if there are any correlates of the cessation of active viral shedding, such as presence of certain immunoglobulins.
Additionally, this study will take a discovery approach to the immune response to better understand how the body recovers or worsens during disease, and if there are opportunities to use that knowledge to develop treatments.